Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

SINOPHARM GROUP CO. LTD.*

(A joint stock limited company incorporated in the People's Republic of China with limited liability and carrying on business in Hong Kong as ��Jt5ttf�%PJ)

(Stock Code: 01099) ANNOUNCEMENT PRINCIPAL FINANCIAL DATA OF SINOPHARM (CNCM LTD) FOR THE THREE MONTHS ENDED 31 MARCH 2015

Reference is made to the overseas regulatory announcement dated 24 April 2015 (the "Announcement") and issued by Sinopharm Group Co. Ltd. (the "Company") in relation to the first quarterly report for the three months ended 31 March 2015 of China National Medicines Corporation Ltd. ("SINOPHARM (CNCM LTD)"), a subsidiary of the Company and whose A shares are listed on the Shanghai Stock Exchange (stock code: 600511).
The board of directors of the Company would like to draw the attention of its shareholders and the public investors to the following principal unaudited financial data of SINOPHARM (CNCM LTD) for the three months ended 31 March 2015 as set out in the Announcement.
1

PRINCIPAL FINANCIAL DATA OF SINOPHARM (CNCM LTD)

Unit: Yuan

Currency: RMB

As at the end of this reporting period As at the end of last year Increase/decrease at the end of this reporting period as compared with the end of last year (%)

Total assets 5,551,468,149.04 5,537,855,521.43 0.25
Net assets attributable to shareholders of the
listed company 2,605,195,349.83 2,480,053,062.83 5.05

From the beginning of the year to the end of the reporting period From the beginning of last year to the end of the reporting period of last year Increase/decrease as compared with the corresponding period of last year (%)

Net cash flow arising from
operating activities 230,693,653.53 55,621,943.85 314.75

From the beginning of the year to the end of the reporting period From the beginning of last year to the end of the reporting period of last year Increase/decrease as compared with the corresponding period of last year (%)

Operating income 2,939,336,476.22 2,704,890,874.74 8.67
Net profit attributable to
shareholders of the listed
company 109,086,123.01 102,018,862.05 6.93
Net profit attributable to
shareholders of the listed company after deducting
non-recurring gains and losses 109,036,376.65 101,968,284.42 6.93
Weighted average return
on net assets (%) 4.29 4.73
Basic earnings per share
Decreased by 0.44 percentage point
(RMB/Share) 0.2278 0.2131 6.90
Diluted earnings per share
(RMB/Share) 0.2278 0.2131 6.90
2
This announcement is made pursuant to Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) and Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.
By order of the Board

Sinopharm Group Co. Ltd. Wei Yulin

Chairman

Shanghai, the PRC
24 April 2015

As at the date of this announcement, the executive directors of the Company are Mr. Wei Yulin and Mr. Li Zhiming; the non-executive directors of the Company are Mr. Chen Qi Yu, Mr. She Lulin, Mr. Wang Qunbin, Mr. Li Yuhua, Mr. Zhou Bin, Mr. Deng Jindong, Mr. Li Dongjiu and Mr. Liu Hailiang; and the independent non-executive directors of the Company are Ms. Li Ling, Mr. Yu Tze Shan Hailson, Mr. Lyu Changjiang, Mr. Tan Wee Seng and Mr. Liu Zhengdong.

* The Company is registered as a non-Hong Kong company under the Hong Kong Companies Ordinance under its

Chinese name and the English name "Sinopharm Group Co. Ltd."

3

distributed by